18 studies found for:    silibinin
Show Display Options
Rank Status Study
1 Completed
Has Results
The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Silibin-Phytosome
2 Completed Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
Condition: Hepatitis C
Intervention: Drug: Silibinin
3 Recruiting A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Dietary Supplement: Silybin-phytosome
4 Not yet recruiting Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Condition: Hepatitis C, Chronic
Interventions: Drug: Legalon® SIL (Silibinin);   Drug: Pegylated interferon alfa2b;   Drug: Ribavirin
5 Recruiting N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Conditions: Diabetic Nephropathies;   Proteinuria;   Oxidative Stress
Interventions: Dietary Supplement: N-acetylcysteine;   Dietary Supplement: silibin;   Dietary Supplement: high-dose silibin;   Dietary Supplement: N-acetylcysteine placebo;   Dietary Supplement: silibin placebo
6 Completed Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability
Conditions: Work Ability;   Depression
Interventions: Drug: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg;   Drug: sugar pill
7 Recruiting Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Conditions: Amatoxin Poisoning;   Amanita Poisoning;   Mushroom Poisoning;   Liver Failure
Intervention: Drug: Legalon SIL (Silibinin)
8 Recruiting THISTLE - The HIV-HCV Silibinin Trial
Conditions: HIV;   Hepatitis C
Intervention: Drug: Intravenous Silibinin (iSIL)
9 Recruiting Glutathione in Diabetic Nephropathy
Conditions: Diabetic Nephropathy;   Proteinuria;   Oxidative Stress
Interventions: Drug: N-acetylcysteine placebo + silibin placebo;   Drug: N-acetylcysteine active + silibin placebo;   Drug: N-acetylcysteine placebo + silibin active;   Drug: N-acetylcysteine active + silibin active;   Drug: N-acetylcysteine active + high-dose silibin active
10 Terminated Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Condition: HCV Recurrence After Liver Transplantation
Interventions: Drug: Silibinin;   Drug: Placebo
11 Completed Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV
Condition: Liver Fibrosis
Interventions: Drug: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex;   Drug: Placebo
12 Terminated Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Condition: Hepatitis C Virus Recurrence
Interventions: Drug: Silibinin (Legalon-SIL);   Drug: Saline
13 Completed Pharmacokinetics of Curcumin in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Curcumin
14 Completed Siliphos in Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Intervention: Drug: Silybin
15 Completed IdB 1016 Treatment for Hepatitis C Disease
Condition: Hepatitis C, Chronic
Intervention: Drug: IdB 1016
16 Completed Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
Condition: Diabetic Nephropathy
Interventions: Drug: placebo;   Drug: Milk Thistle extract
17 Withdrawn Randomized Controlled Trial of Silymarin in Asthma
Condition: Atopic Asthma
Interventions: Drug: Oral Silymarin;   Drug: Oral Silymarin, maintenance dose;   Drug: Placebo
18 Recruiting Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Condition: Non-alcoholic Fatty Liver Disease
Intervention: Drug: Sillymarin

Indicates status has not been verified in more than two years